[Cp*RhCl2]2, catalyzes efficiently the transferhydrogenation of various quaternary pyridinium salts under mild conditions, affording not only piperidines but also 1,2,3,6‐tetrahydropyridines in a highly chemoselective fashion, depending on the substitution pattern at the pyridinium ring. The reduction is conducted in azeotropic formic acid/triethylamine (HCOOH‐Et3N) mixture at 40 °C, with catalyst loadings
Azaquinazoline inhibitors of atypical protein kinase C
申请人:CANCER RESEARCH TECHNOLOGY LIMITED
公开号:US10414763B2
公开(公告)日:2019-09-17
The present application provides a compound of formula (I)
and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
本申请提供了一种式 (I) 的化合物
和/或其盐,其中 R1、G 和 X 如本文所定义。式(I)化合物和/或其盐具有 PKC 抑制活性,可用于治疗增殖性疾病。还提供了包含式(I)化合物和/或其盐的组合物。
AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
申请人:Cancer Research Technology Limited
公开号:EP3129372B1
公开(公告)日:2020-12-16
[EN] AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS AZAQUINAZOLINE DE LA PROTÉINE KINASE C ATYPIQUE
申请人:IGNYTA INC
公开号:WO2015148597A1
公开(公告)日:2015-10-01
The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.